Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization of products ...

Novo Nordisk, for its part ... Novo pens $285M biobucks deal to use Ascendis' tech to create monthly GLP-1 agonist Still, Novo has been less fortunate with external cardiometabolic efforts ...

Ascendis Pharma announced the expiration of the regulatory waiting period for its collaboration agreement with Novo Nordisk, clearing the path for the development and commercialization of products ...

A once-weekly injection consisting of a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (Wegovy) led to ...

Lead product MBX 2109 is a prodrug of parathyroid hormone (PTH), which is deficient in hypoparathyroidism, and a would rival to Ascendis ... 1/GIP drugs – like Novo Nordisk's semaglutide and ...

Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...

Novo Nordisk posts disappointing update related to its new weight loss drug CagriSema. Novo Nordisk stock is now down 25% ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

In a report released on December 23, Joseph Schwartz from Leerink Partners maintained a Buy rating on Ascendis Pharma (ASND – Research Report), ...

Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.

Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.

Bad news for Novo Nordisk (NVO 4.37%) Friday was good news for Eli Lilly (LLY 3.71%) and Viking Therapeutics (VKTX 0.17%), its two main rivals in the field of weight loss drugs. This morning ...